• Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine, 339, 511.
  • Ballas, S.K. (2001) Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Seminars in Hematology, 38 (Suppl. 1), 3036.
  • Brittenham, G.M., Farrel, D.E., Harris, J.W., Feldman, E.S., Danish, E.H., Muir, W.A., Tripp, J.H. & Bellon, E.M. (1982) Magnetic susceptibility measurement of human iron stores. New England Journal of Medicine, 307, 16711675.
  • Brittenham, G.M., Cohen, A.R., McLaren, C.E., Martin, M.B., Griffith, P.M., Nienhuis, A.W., Young, N.S., Allen, C.J., Farrell, D.E. & Harris, J.W. (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. American Journal of Hematology, 42, 8185.
  • Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, P., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Dfaffer, C., Marks, P. & Alberti, D. (2006) A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107, 34553462.
  • Fischer, R., Harmatz, P. & Nielsen, P. (2006) Does liver biopsy overestimate liver iron concentration? Blood, 108, 17751776.
  • Gabutti, V. & Piga, A. (1996) Results of long-term iron-chelating therapy. Acta Haematologica, 95, 2636.
  • Hagar, R.W. & Vichinsky, E.P. (2000) Major changes in sickle cell disease. Advances in Pediatrics, 47, 249272.
  • Hanley, J.A. & Lippman-Hand, A. (1983) If nothing goes wrong, is everything all right? Interpreting zero numerators. The Journal of the American Medical Association, 249, 17431745.
  • Jensen, P.D., Jensen, F.T., Christensen, T., Nielsen, J.L. & Ellegaard, J. (2003) Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood, 101, 9196.
  • Manci, E.A., Culberson, D.E., Yang, Y.M., Gardner, T.M., Powell, R., Haynes, J. Jr , Shah, A.K. & Mankad, V.N. (2003) Investigators of the Cooperative Study of sickle cell disease. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology, 123, 359365.
  • McLaren, G.D., Muir, W.A. & Kellermeyer, R.W. (1983) Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Critical Reviews in Clinical Laboratory Sciences, 19, 205266.
  • National Institutes of Health. (2002) Management and Therapy of Sickle Cell Disease. National Heart, Lung, and Blood Institute, URL (NIH Publication No. 96-2117:153–160).
  • Olivieri, N.F. & Brittenham, G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood, 89, 739761.
  • Porter, J.B. (2001) Practical management of iron overload. British Journal of Haematology, 115, 239252.
  • Schrier, S.L. & Angelucci, E. (2005) New strategies in the treatment of thalassemias. Annual Review of Medicine, 56, 157171.
  • Styles, L.A. & Vichinsky, E. (1994) Effects of a long-term transfusion regimen on sickle cell-related illnesses. Journal of Pediatrics, 125, 909911.
  • Tanner, J.M. (1978) Fetus into Man: Physical Growth from Conception to Maturity. Harvard University Press, Cambridge, MA.
  • The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP2) Trial Investigators. (2005) Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine, 353, 27692778.
  • Treadwell, M.J., Law, A.W., Sung, J., Hackney-Stephens, E., Quirolo, K., Murray, E., Glendenning, G.A. & Vichinsky, E. (2005) Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatric Blood and Cancer, 44, 500507.
  • Vanorden, H.E. & Hagemann, T.M. (2006) Deferasirox — an oral agent for chronic iron overload. Annals of Pharmacotherapy, 40, 11101117.
  • Vichinsky, E., Butensky, E., Fung, E., Hudes, M., Theil, E., Ferrell, L., Williams, R., Louie, L., Lee, P.D. & Harmatz, P. (2005) Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. American Journal of Hematology, 80, 7074.
  • Wanko, S.O. & Telen, M.J. (2005) Transfusion management in sickle cell disease. Hematology/Oncology Clinics of North America, 19, 803826.